The effect of blood clotting and clot reducing medication in blood drawn from patients undergoing liver or pancreas surgery.

• Conditions: liver tranplantation, partial hepatectomy, pancreatectomy, cirrhosis, anticoagulation, procoagulants

• Registration Number: NL-OMON28973
• Lead Sponsor: Kings College Hospital NHS Foundation Trust

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

Liver transplantation, right / extended right hepatectomy or pancreatectomy at Kings College Hospital.

- >18 years

Exclusion Criteria

Exclusion criteria study group:

- Acute liver failure

Study & Design

• Study Type: Not specified
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary end point of our study is the difference in change of the various parameters of the thrombin generation curve after in vitro addition of a fixed dose of a pro- or anticoagulant drug between patient and control samples. This<br>degree of change indicates the pro- or anticoagulant efficacy of a certain drug as described previously. (Potze W, et al. <br /><br>Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. (PLoS One 2014 Feb 4&#894;9(2):e88390)

Secondary Outcome Measures

Name	Time	Method
We do not have any secondary outcome measures, but will assess several other laboratory parameters which we will use to describe the cohort such as the individual coagulation factors, PT, INR, APTT, Fibrinogen, Platelet count and Hb. Indicators of liver function such as GGT, ALT, AST, NH3, alpha1 antitrypsin and ceruloplasmin.